Myriad Genetics Stock Price, News & Analysis

Myriad Genetics (NASDAQ: MYGN) highlighted key clinical studies from 2022, showcasing its commitment to enhancing genetic testing accessibility and equity. Significant advancements include the development of RiskScore®, a breast cancer polygenic risk score for diverse populations, and the improved efficacy of GeneSight® in treating major depressive disorder. Research also led to a comprehensive carrier screening panel for genetic diseases and the ability to execute the MyChoice® HRD assay in decentralized locations. These innovations illustrate Myriad's focus on reducing healthcare disparities and optimizing patient outcomes.

Myriad Genetics (NASDAQ: MYGN) is advancing non-invasive prenatal screening (NIPS) with its products Prequel and the upcoming FirstGene test, leveraging AMPLIFY technology. The recent update by the American College of Medical Genetics and Genomics (ACMG) endorses NIPS for various chromosomal abnormalities. Prequel already screens for sex-chromosome aneuploidies and microdeletions, enhancing accuracy through increased fetal fraction. The new FirstGene test will combine multiple screening modalities into a single blood draw, expected to launch in Q3 2023, offering significant improvements in prenatal screening.

Myriad Genetics (NASDAQ: MYGN) announced that its CEO, Paul J. Diaz, and Chief Scientific Officer, Dale Muzzey, will present at the 41^st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be available via a live webcast on the company's Investor Relations website, with an archived version accessible later that day. Additionally, COO Nicole Lambert will join a panel discussion on global precision medicine at the Goodwin + KPMG Symposium on January 11, 2023, at 10:45 a.m. PST/1:45 p.m. EST.

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced the appointment of five senior executives to enhance its product management and commercial strategy. Key new hires include Marc Leighton as SVP for Product Management, Glenn Farrell as CMO, and others responsible for lab transformation and business development. Their collective experience aims to bolster Myriad's growth in genetic testing and precision medicine. CEO Paul J. Diaz expressed confidence that their leadership will drive sustainable growth and innovation, positioning the company for future success.

Myriad Genetics (NASDAQ: MYGN) has announced positive results from a longitudinal study validating its MyRisk™ Hereditary Cancer test with RiskScore® as an accurate breast cancer risk predictor. Presented at the 2022 San Antonio Breast Cancer Symposium, the study involved over 130,000 women and demonstrated that RiskScore can better stratify high- and low-risk patients compared to standard assessments. This advancement in precision medicine could enhance breast cancer prevention strategies, allowing women to make informed management decisions regarding their health.

Myriad Genetics (NASDAQ: MYGN) presented new data at the 2022 San Antonio Breast Cancer Symposium, focusing on a spotlight discussion regarding breast cancer risk prediction. The discussion covered a study involving 130,058 women, highlighting the use of a combined risk score based on polygenic risk scores and the Tyrer-Cuzick model. The findings aim to enhance breast cancer prevention and screening strategies. Myriad showcased various products, including MyRisk, MyChoice CDx, and EndoPredict, emphasizing their role in personalized cancer care.

Myriad Genetics, Inc. (NASDAQ: MYGN) will present at the 41^st Annual NSGC meeting from Nov. 16-19, 2022, focusing on expanding access to genetic insights for prenatal and hereditary cancer. CEO Paul J. Diaz emphasizes collaboration with genetic counselors to enhance accessibility and affordability. The company will host a CEU symposium and promote its products, including MyRisk™ with RiskScore and Prequel®. Additionally, Myriad plans to livestream key discussions on health equity and precision medicine.

Myriad Genetics (MYGN) announced the launch of UroSuite, a suite of genetic tests for prostate cancer care. This comprehensive solution offers multiple tests including Prolaris and MyRisk, allowing healthcare providers to personalize treatment effectively. The platform also features a Precise Treatment Registry, aiming to enhance the accessibility of genetic insights. Myriad is focused on addressing educational gaps in genetic testing adoption, providing clinicians with tools for streamlined reporting and patient management. The company aims to improve patient outcomes in precision medicine.

Myriad Genetics (NASDAQ: MYGN) announced a new study published in JCO Precision Oncology, which developed a breast cancer polygenic risk score (PRS) for women of all ancestries. This innovative PRS methodology enhances risk assessment accuracy using genetic ancestry markers, providing a tailored risk evaluation that incorporates both genetic and clinical variables. The MyRisk™ Hereditary Cancer Test has already integrated this advancement, improving access to genetic testing and aiming to reduce healthcare disparities for breast cancer risk.